Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHOENIX-GC2 trial of systemic plus intraperitoneal chemotherapy versus systemic chemotherapy for high-risk advanced gastric cancer
jRCT2031200087Phase 3Active, not recruiting
- Start
- Oct 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tegafur, paclitaxel, docetaxel and oxaliplatin in gastric adenocarcinoma (6 arms). Primary endpoint: Disease-free survival. Started Oct 2020; status: active, not recruiting.
02
Drugs
tegafurpaclitaxeldocetaxeloxaliplatin
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on jRCT2031200087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200087.